FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Huub van Vliet

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Phenomena

Bleeding Time

Anatomy

Physiology

Platelet Aggregation

Procedures

Platelet Function Tests

Co-author Network

Publications

TOP 3
Janine E van Loon; Huub H D M van Vliet; Maarten L Simoons; Hans Ulrichts; Philip G de Groot; Peter P T de Jaegere; Moniek P M de Maat; Frank W G Leebeek
The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention.
Jan Jacques Michiels; Huub H D M van Vliet; Zwi Berneman; Wilfried Schroyens; Alain Gadisseur
Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Jan Jacques Michiels; Huub H D M van Vliet
Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Huub van Vliet (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Janine E van Loon; Huub H D M van Vliet; Maarten L Simoons; Hans Ulrichts; Philip G de Groot; Peter P T de Jaegere; Moniek P M de Maat; Frank W G Leebeek
The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention.
Thrombosis and haemostasis 2011;106(1):165-71.
2009: Jan Jacques Michiels; Huub H D M van Vliet; Zwi Berneman; Wilfried Schroyens; Alain Gadisseur
Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Acta haematologica 2009;121(2-3):167-76.
2009: Jan Jacques Michiels; Huub H D M van Vliet
Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Acta haematologica 2009;121(2-3):154-66.
2009: Jan Jacques Michiels; Zwi Berneman; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Huub H D M van Vliet
Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
Acta haematologica 2009;121(2-3):85-97.
2008: Huub H D M van Vliet; Mies C Kappers-Klunne; Frank W G Leebeek; Jan Jacques Michiels
PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
Thrombosis and haemostasis 2008;100(3):462-8.
2007: Marieke J H A Kruip; Huub H D M van Vliet; Peter M T Pattynama; Alice Kars; Anton H van den Meiracker; Kon-Siong G Jie; Frank W G Leebeek
Evaluation of the AutoDimer D-dimer assay for the exclusion of pulmonary embolism.
Thrombosis and haemostasis 2007;97(2):325-6.
2007: Jan Jacques Michiels; Huub H D M van Vliet; Zwi Berneman; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Ann van der Velden; Ulrich Budde
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2007;13(1):14-34.
2006: Jan Jacques Michiels; Zwi Berneman; Wilfried Schroyens; Peter J Koudstaal; Jan Lindemans; H A M Neumann; Huub H D M van Vliet
Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Platelets 2006;17(8):528-44.
2006: Tamara N Bongers; Moniek P M de Maat; Mary-Lou P J van Goor; Vinod Bhagwanbali; Huub H D M van Vliet; Encarnación B Gómez García; Diederik W J Dippel; Frank W G Leebeek
High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.
Stroke; a journal of cerebral circulation 2006;37(11):2672-7.
2006: Jan Jacques Michiels; Zwi Berneman; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Ann van de Velde; Huub H D M van Vliet
Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(4):397-420.
2006: Jan Jacques Michiels; Zwi Berneman; Wilfried Schroyens; Guido Finazzi; Ulrich Budde; Huub H D M van Vliet
The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Seminars in thrombosis and hemostasis 2006;32(6):589-604.
2006: Jan Jacques Michiels; Zwi Berneman; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Ulrich Budde; Huub H D M van Vliet
Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.
Seminars in thrombosis and hemostasis 2006;32(6):577-88.
2006: Jan Jacques Michiels; Zwi Berneman; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Ann van de Velde; Huub H D M van Vliet
Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(3):277-95.
2006: Jan Jacques Michiels; Zwi Berneman; Wilfried Schroyens; Peter J Koudstaal; Jan Lindemans; Huub H D M van Vliet
Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin.
Blood cells, molecules & diseases 2006;36(2):199-205.
2005: Jan Jacques Michiels; Alain Gadisseur; Ulrich Budde; Zwi Berneman; Marc van der Planken; Wilfried Schroyens; Ann van de Velde; Huub H D M van Vliet
Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Seminars in thrombosis and hemostasis 2005;31(5):577-601.
2004: Jan Jacques Michiels; Zwi N Berneman; Marc van der Planken; Wilfried Schroyens; Ulrich Budde; Huub H D M van Vliet
Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2004;15(4):323-30.
2004: Jan Jacques Michiels; Zwi N Berneman; Wilfried Schroyens; Huub H D M van Vliet
Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.
Platelets 2004;15(2):67-84.
2004: Gerard A J Jansen; Huub H D M van Vliet; Hans Vermeij; Erik A M Beckers; Frank W G Leebeek; Pieter Sonneveld; Dick J van Rhenen
Functional characteristics of photochemically treated platelets.
Transfusion 2004;44(3):313-9.
2004: Diederik W J Dippel; Fop van Kooten; Frank W G Leebeek; Huub H D M van Vliet; Ajnira Mehicevic; Simon S C Li; Peter J Koudstaal
What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke?
Cerebrovascular diseases (Basel, Switzerland) 2004;17(4):296-302.
2004: Mark-David Levin; Mies C Kappers-Klunne; Kees Sintnicolaas; Bronno van der Holt; Huub H D M van Vliet; Bob Löwenberg; Mars B van't Veer
The value of alloantibody detection in predicting response to HLA-matched platelet transfusions.
British journal of haematology 2004;124(2):244-50.
2003: Kirill Skomorovski; Hila Harpak; Anton Ianovski; Moshe Vardi; Trudi P Visser; Simone C C Hartong; Huub H D M van Vliet; Gerard Wagemaker; Zvia Agur
New TPO treatment schedules of increased safety and efficacy: pre-clinical validation of a thrombopoiesis simulation model.
British journal of haematology 2003;123(4):683-91.
2002: Encarnación B Gómez García; Geert-Jan Brouwers; Mies C Kappers-Klunne; Frank W G Leebeek; Huub H D M van Vliet
[Intermittent thrombocytopenia as a manifestation of Von Willebrand's disease].
Nederlands tijdschrift voor geneeskunde 2002;146(25):1192-5.
2002: Jeroen de Jonge; Theo H N Groenland; Herold J Metselaar; Jan N M Ijzermans; Huub H D M van Vliet; Loes Visser; Hugo W Tilanus
Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP).
Anesthesia and analgesia 2002;94(5):1127-31, table of contents.
2002: Jan Jacques Michiels; Ann van de Velde; Huub H D M van Vliet; Marc van der Planken; Wilfried Schroyens; Zwi Berneman
Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Seminars in thrombosis and hemostasis 2002;28(2):111-32.
2001: Mies C Kappers-Klunne; M de Haan; P C Struijk; Huub H D M van Vliet
Serum thrombopoietin levels in relation to disease status in patients with immune thrombocytopenic purpura.
British journal of haematology 2001;115(4):1004-6.
2001: Jan Jacques Michiels; Ulrich Budde; Marc van der Planken; Huub H D M van Vliet; Wilfried Schroyens; Zwi Berneman
Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Best practice & research. Clinical haematology 2001;14(2):401-36.
2001: A H Loof; Huub H D M van Vliet; Mies C Kappers-Klunne
Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura.
British journal of haematology 2001;112(4):1087-8.
1999: Frank W G Leebeek; M R Schipperus; Huub H D M van Vliet
Coagulation factor levels in solvent/detergent-treated plasma.
Transfusion 1999;39(10):1150-1.
1997: Perry van Genderen; FJ Prins; I S Lucas; D van de Moesdijk; Huub H D M van Vliet; R van Strik; Jan Jacques Michiels
Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count.
British journal of haematology 1997;99(4):832-6.
1997: Perry van Genderen; Huub H D M van Vliet; FJ Prins; D van de Moesdijk; R van Strik; Freek Jan Zijlstra; Ulrich Budde; Jan Jacques Michiels
Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma.
Annals of hematology 1997;75(5-6):215-20.
1997: Mies C Kappers-Klunne; D M Boon; W C Hop; Jan Jacques Michiels; J Stibbe; C van der Zwaan; Peter J Koudstaal; Huub H D M van Vliet
Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases.
British journal of haematology 1997;96(3):442-6.
1996: Jan Jacques Michiels; Perry van Genderen; Jan Lindemans; Huub H D M van Vliet
Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.
Leukemia & lymphoma 1996;22 Suppl 1():47-56.
1996: D M Boon; Huub H D M van Vliet; R Zietse; M C Kappers-Klunne
The presence of antibodies against a PF4-heparin complex in patients on haemodialysis.
Thrombosis and haemostasis 1996;76(3):480.
1996: Perry van Genderen; I S Lucas; R van Strik; VD Vuzevski; F J Prins; Huub H D M van Vliet; Jan Jacques Michiels
Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation.
Thrombosis and haemostasis 1996;76(3):333-8.
1996: Johanna van der Bom; Michiel Bots; Huub H D M van Vliet; Huibert A P Pols; Albert Hofman; Diederick Grobbee
Antithrombin and atherosclerosis in the Rotterdam Study.
Arteriosclerosis, thrombosis, and vascular biology 1996;16(7):864-7.
1996: Perry van Genderen; Ulrich Budde; Jan Jacques Michiels; R van Strik; Huub H D M van Vliet
The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count.
British journal of haematology 1996;93(4):962-5.
1996: H Engel; L Zwang; Huub H D M van Vliet; Jan Jacques Michiels; J Stibbe; Jan Lindemans
Phenotyping and genotyping of coagulation factor V Leiden.
Thrombosis and haemostasis 1996;75(2):267-9.
1995: Jan Jacques Michiels; L van der Luit; Huub H D M van Vliet; K Jochmans; Willy Lissens
Nonsense mutation Arg197stop in a Dutch family with type 1 hereditary antithrombin (AT) deficiency causing thrombophilia.
Thrombosis research 1995;78(3):251-4.
1995: Perry van Genderen; W Terpstra; Jan Jacques Michiels; L Kapteijn; Huub H D M van Vliet
High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease.
Thrombosis and haemostasis 1995;73(5):891-2.
1995: D M Boon; M C Kappers-Klunne; Jan Jacques Michiels; J Stibbe; Huub H D M van Vliet
Heparin-induced thrombocytopenia and thrombosis: a potential fatal complication in a routine treatment.
The Netherlands journal of medicine 1995;46(3):146-52.
1995: Perry van Genderen; Jan Jacques Michiels; R van Strik; Jan Lindemans; Huub H D M van Vliet
Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin.
Thrombosis and haemostasis 1995;73(2):210-4.
1994: Perry van Genderen; Tom Vink; Jan Jacques Michiels; M B van 't Veer; Jan J Sixma; Huub H D M van Vliet
Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen.
Blood 1994;84(10):3378-84.
1994: D M Boon; Jan Jacques Michiels; J Stibbe; Huub H D M van Vliet; M C Kappers-Klunne
Heparin-induced thrombocytopenia and antithrombotic therapy.
Lancet 1994;344(8932):1296.
1994: Perry van Genderen; Jan Jacques Michiels; S C van der Poel-van de Luytgaarde; Huub H D M van Vliet
Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count.
Annals of hematology 1994;69(2):81-4.
1994: Jan Jacques Michiels; Perry van Genderen; Huub H D M van Vliet
Erythromelalgia and arterial thrombophilia in thrombocythemia.
Annals of the New York Academy of Sciences 1994;714():318-21.
1993: Jan Jacques Michiels; Peter J Koudstaal; A H Mulder; Huub H D M van Vliet
Transient neurologic and ocular manifestations in primary thrombocythemia.
Neurology 1993;43(6):1107-10.
1992: Michiel Bots; P J Breslau; E Briët; A M de Bruyn; Huub H D M van Vliet; F A van den Ouweland; P T de Jong; Albert Hofman; Diederick Grobbee
Cardiovascular determinants of carotid artery disease. The Rotterdam Elderly Study.
Hypertension 1992;19(6 Pt 2):717-20.
1987: Jan Jacques Michiels; M E Prins; A Hagermeijer; P Brederoo; J van der Meulen; Huub H D M van Vliet; J Abels
Philadelphia chromosome-positive thrombocythemia and megakaryoblast leukemia.
American journal of clinical pathology 1987;88(5):645-52.
1987: Huub H D M van Vliet; M C Kappers-Klunne; J W van der Hel; J Abels
Antibodies against glycosphingolipids in sera of patients with idiopathic thrombocytopenic purpura.
British journal of haematology 1987;67(1):103-8.
1986: Huub H D M van Vliet; M C Kappers-Klunne; J Abels
Pseudothrombocytopenia: a cold autoantibody against platelet glycoprotein GP IIb.
British journal of haematology 1986;62(3):501-11.
1985: Jan Jacques Michiels; J Abels; J Steketee; Huub H D M van Vliet; VD Vuzevski
Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia.
Annals of internal medicine 1985;102(4):466-71.
1984: Jan Jacques Michiels; J Stibbe; E Vellenga; Huub H D M van Vliet
Prophylaxis of thrombosis in antithrombin III-deficient women during pregnancy and delivery.
European journal of obstetrics, gynecology, and reproductive biology 1984;18(3):149-53.